Showing 4211-4220 of 5300 results for "".
- Study Reveals TikTok's Impact on Psoriasis Treatment Understandinghttps://practicaldermatology.com/news/study-reveals-tiktoks-impact-on-psoriasis-treatment-understanding/2462223/A new study published in the Journal of Drugs in Dermatology offers a glimp
- Important FDA Approvals in 2023 Lead to New, Exciting Treatments in 2024https://practicaldermatology.com/news/important-fda-approvals-in-2023-lead-to-new-exciting-treatments-in-2024/2462219/A slew of big approvals for new therapies in 2023 has increased the armamentarium for dermatologists treating many conditions going into 2024, according to an opening presentation at Maui Derm 2024. <
- Researchers Identify Factors Limiting New Treatment Decisions for HShttps://practicaldermatology.com/news/factors-affecting-treatment-selection-among-patients-with-hidradenitis-suppurativa/2462211/Researchers seeking to address the gap between evidence-based guidelines and clinical practice in the treatment of hidradenitis suppurativa (HS) have identified several factors influencing patient decision-making. The open-ended, two-center study, conducted through open-ended interviews
- Navigating Antibiotic Use for Acne and Rosacea: Clinician Insights and Considerationshttps://practicaldermatology.com/news/navigating-antibiotic-use-for-acne-and-rosacea-clinician-insights-and-considerations/2462208/Growing apprehensions surrounding antibiotic resistance in acne and rosacea treatments, coupled with their linked
- FDA Deems Vaporized Hydrogen Peroxide an Established Method of Sterilizationhttps://practicaldermatology.com/news/fda-deems-vaporized-hydrogen-peroxide-an-established-method-of-sterilization/2462205/The U.S. Food and Drug Administration (FDA) announced that it now considers vaporized hydrogen peroxide (VHP) as an established method of sterilization for medical devices. In what the agency called a recognition of its long-time effectiveness, it revised the final guidance on the
- Vidac Queues Up Phase 2b Study for Potential Actinic Keratosis Therapyhttps://practicaldermatology.com/news/vidac-pharma-to-conduct-phase-2b-study-for-actinic-keratosis-therapeutic-candidate-vda-1102-with-centroderm/2462192/Vidac Pharma Holdings recently announced the commencement of a Phase 2b trial for its candidate therapy (VDA-1102) to treat actinic keratosis (AK), and has engaged with a research team from a leading clinical dermatology clinical research institute (CentroDerm GmbH). According to the ma
- Can-Fite Receives Positive Response from FDA for Psoriasis Pediatric Planhttps://practicaldermatology.com/news/can-fite-receives-positive-response-from-fda-for-psoriasis-pediatric-plan/2462187/The U.S. Food and Drug Administration (FDA) gave a positive response to a study plan for piclidenoson in children suffering from psoriasis. The plan allows for children to enroll in the phase 3 pivotal clinical study aiming at registering the drug with both the FDA as well as the Europe
- Kymera Update: First Patient Dosed in Phase 2 AD Clinical Trial of KT-474, a First-in-Class Investigational IRAK4 Degraderhttps://practicaldermatology.com/news/kymera-update-first-patient-dosed-in-phase-2-ad-clinical-trial-of-kt-474-a-first-in-class-investigational-irak4-degrader/2462177/The first patient has been dosed in the Phase 2 clinical trial (ADVANTA) evaluating KT-474 in AD, generating a $15 million milestone payment under its collaboration with Sanofi. KT-474 is an oral IRAK4 degrader, in development for the treatment of IL-1R/TLR-driven complex inflamma
- Study: Individuals With Acne Face Social and Professional Stigmahttps://practicaldermatology.com/news/study-individuals-with-acne-face-social-and-professional-stigma/2462175/Individuals with acne face social and professional stigma, and people with darker skin tones and more severe acne are disproportionately more likely to face greater stigma. These results, published in JAMA Dermatology, highlight the need to identify ways to
- Vtama Cream, 1% Continues to Wow in Scalp and Neck PsOhttps://practicaldermatology.com/news/vtama-cream-1-continues-to-wow-in-scalp-and-neck-pso/2462174/VTAMA (tapinarof) cream, 1% performed well in the treatment of psoriasis on the head and neck, according to its Phase 4, open-label trial. In the two 12-week Phase 3 pivotal studies (PSOARING 1 and 2; N=1025), VTAMA cream demonstrated a Physician Global Assessment (PGA) success rat